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Available online 20 January 2016Beta-amyloid (Aβ) deposition can be observed in primary progressive aphasia (PPA) and progressive apraxia of
speech (PAOS).While it is typically associatedwith logopenic PPA, there are exceptions thatmakepredictingAβ sta-
tus challenging based on clinical diagnosis alone. We aimed to determine whether MRI regional volumes or clinical
data could help predict Aβ deposition. One hundred and thirty-nine PPA (n= 97; 15 agrammatic, 53 logopenic, 13
semantic and 16 unclassiﬁed) and PAOS (n=42) subjects were prospectively recruited into a cross-sectional study
and underwent speech/language assessments, 3.0 T MRI and C11-Pittsburgh Compound B PET. The presence of Aβ
was determined using a 1.5 SUVR cut-point. Atlas-based parcellation was used to calculate gray matter volumes of
42 regions-of-interest across the brain. Penalized binary logistic regression was utilized to determine what combi-
nation ofMRI regions, andwhat combination of speech and language tests, best predicts Aβ (+) status. The optimal
MRI model and optimal clinical model both performed comparably in their ability to accurately classify subjects ac-
cording to Aβ status. MRI accurately classiﬁed 81% of subjects using 14 regions. Small left superior temporal and in-
ferior parietal volumes and large left Broca's area volumes were particularly predictive of Aβ (+) status. Clinical
scores accurately classiﬁed 83% of subjects using 12 tests. Phonological errors and repetition deﬁcits, and absence
of agrammatism andmotor speech deﬁcits were particularly predictive of Aβ (+) status. In comparison, clinical di-
agnosiswas able to accurately classify 89% of subjects. However, theMRImodel performedwell in predicting Aβ de-
position in unclassiﬁed PPA. Clinical diagnosis provides optimumprediction of Aβ status at the group level, although
regional MRI measurements and speech and language testing also performed well and could have advantages in
predicting Aβ status in unclassiﬁed PPA subjects.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Volumetric MRI1. Introduction
Patients with primary neurodegenerative speech and language dis-
orders can present either with primary progressive aphasia (PPA)
(Mesulam, 2001; Gorno-Tempini et al., 2011) or progressive apraxia of
speech (PAOS) (Josephs et al., 2012, 2013). The term PPA is reserved
for a neurodegenerative disorder in which the most salient feature is
language dysfunction (Mesulam, 1982, 2001). Three variants of PPA
have been described which are each characterized by different patterns
of language impairment (Gorno-Tempini et al., 2011). The agrammatic
variant (agPPA) is characterized by written and verbal language that is
grammatically ﬂawed and sometimes with apraxia of speech (AOS);y, Mayo Clinic, 200 1st St SW,
twell).
. This is an open access article underthe semantic variant (svPPA) is characterized by anomia and loss of
single-word knowledge; and the logopenic variant (lvPPA) is character-
ized by anomia without loss of word knowledge, difﬁculty with sen-
tence repetition and phonologic errors. In contrast, the term PAOS
describes a neurodegenerative disorder in which AOS is the presenting
and most dominant clinical feature (Josephs et al., 2012, 2013). These
subjects can present with slow speech rate, articulatory distortions,
distorted sound substitutions and segmentation of syllables inmultisyl-
labic words or across words. Language impairment can be present,
although it must be less severe than the AOS (Josephs et al., 2013).
The pathological underpinnings of the PPA variants and PAOS are
variable, typically having either a variant of frontotemporal lobar de-
generation (FTLD) or Alzheimer's disease (AD) (Kertesz et al., 2005;
Josephs et al., 2006; Harris et al., 2013; Mesulam et al., 2014). Clinical
diagnosis is relatively helpful in predicting pathology, with lvPPA sub-
jects usually having AD pathology and PAOS, agPPA and svPPA subjectsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014). However, discordant cases are common, with AD pathology, or
beta-amyloid (Aβ) deposition on PET, observed in 18% of PAOS(Josephs
et al., 2014), 0–30% of agPPA (Rabinovici et al., 2008; Leyton et al., 2011;
Chare et al., 2014, Josephs et al., 2014) and 11–21% of svPPA (Rabinovici
et al., 2008; Leyton et al., 2011; Chare et al., 2014; Josephs et al., 2014)
cases. Conversely, up to 46% of some series of lvPPA subjects do not
have AD pathology (Harris et al., 2013). In addition, a large proportion
of subjects with language impairment does not fulﬁll diagnostic criteria
for one of the PPA variants, and hence remain unclassiﬁed (Sajjadi et al.,
2012; Mesulam et al., 2014; Wicklund et al., 2014). Other biomarkers
are therefore needed that can help predict the presence of AD in PPA
and PAOS and hence help guide potential treatments. The PPA variants
and PAOS are each associated with speciﬁc patterns of atrophy
(Gorno-Tempini et al., 2004; Josephs et al., 2012, 2013), although it is
unknown whether these patterns vary according to the presence of
AD pathology, particularly within PPA syndromes, and hence whether
MRI could provide clues to the underlying pathology.
The aim of this study was to determine whether a model based on
regional gray matter volume data measured from MRI could predict
the presence of Aβ deposition on PET in PPA variants and PAOS. We
also aimed to compare this MRI model to a model based on speech
and language test data, and to determinewhether either theMRI or clin-
ical model could in fact do better than clinical diagnosis.
2. Methods
2.1. Subject recruitment
All subjects that presented with a predominant speech or language
complaint and fulﬁlled diagnostic criteria for PPA (Mesulam, 2001) or
PAOS (Josephs et al., 2012, 2013) were prospectively recruited from
the Department of Neurology, Mayo Clinic, between July 1st 2010 and
June 1st 2014. All subjects underwent a detailed neurological and
speech and language evaluation, as previously described (Josephs
et al., 2012), and diagnoses were rendered by consensus between two
speech-language pathologists (JRD and EAS) after reviewing video re-
cordings and speech-language test results for each subject. All diagnoses
were made blinded to any neurological or neuroimaging ﬁndings. All
subjects also underwent a volumetricMRI and an Aβ PET scan. The neu-
rological and speech and language evaluations, MRI and PET scans were
all performedwithin 72h. A total of 143 subjectswere recruited into the
study. Four subjects were excluded because they either could not per-
form theMRI or theMRI was of poor quality. Of the remaining 139 sub-
jects, 97 were diagnosed with a PPA variant (Gorno-Tempini et al.,
2011) (15 agPPA, 13 svPPA, 53 lvPPA and 16 unclassiﬁed PPA, UCPPA)Table 1
Subject demographics.
Total cohort
N 139
PiB SUVR 1.3 (1.2–2.0)
Female gender, no. (%) 70 (50%)
Education, yrs. 16 (13–18)
Apolipoprotein e4, no. (%)* 38/120 (32%)
Age at exam, yrs. 69 (61–73)
Age at onset, yrs. 66 (58–70)
Disease duration, yrs. 3.0 (2.0–4.5)
Mini-Mental State Examination, (/30) 28 (24–29)
Clinical Dementia Rating Scale sum of boxes, (/18) 1.0 (0–3.0)
Clinical dx., no. (%)
agPPA 15 (11%)
svPPA 13 (9%)
lvPPA 53 (38%)
UCPPA 16 (12%)
PAOS 42 (30%)
Data shown as median (inter-quartile range).and 42 were diagnosed with PAOS (Josephs et al., 2012, 2013), accord-
ing to our previously published criteria (Botha et al., 2015). In three of
the UCPPA subjects, anomia was the predominant feature, with ﬂuent
speech, but these subjects did not meet criteria for lvPPA or svPPA
(two of these were Aβ (+)). We have previously classiﬁed these sub-
jects as progressive ﬂuent aphasia (Botha et al., 2015). Of the remaining
UCPPA subjects, two resembled lvPPA but lacked phonological errors
and/or repetition deﬁcits (both Aβ (−)), two resembled lvPPA but
had agrammatism (both Aβ (−)), one had impaired comprehension
of sentences and loss of word meaning (Aβ (+)), and one subject
(Aβ (−)) had prominent anomiawith sparedword andobjectmeaning,
together with AOS and dysarthria. In two UCPPA subjects, impairment
was too severe to classify (both Aβ (−)) and, in ﬁve, impairment was
so mild that discrepancies or patterns of impairment could not be ap-
preciated (all Aβ (−)).
Apolipoprotein genotyping and assessment for the presence of
progranulin (Baker et al., 2006) or microtubule associated protein tau
mutations (Hutton et al., 1998), and C9ORF72 repeat expansions
(Dejesus-Hernandez et al., 2011) were performed as previously
described (Whitwell et al., 2012; Flanagan et al., 2015). The study was
approved by the Mayo Clinic IRB. All patients consented for enrolment
into the study.2.2. Speech and language data
Fourteen speech and language tests were entered into the predictive
model. These tests were selected to assess the presence or absence of
each diagnostic feature of each clinical variant (Wicklund et al., 2014).
The fourteen tests include the Token Test Part V (DeRenzi and
Vignolo, 1962) to assess comprehension of complex sentences, the au-
ditory word recognition subtest of the Western Aphasia Battery
(WAB) (Kertesz, 2007) to assess single word comprehension, the read-
ing and writing irregular and non-word subtests of the WAB to assess
surface dyslexia or dysgraphia, the repetition subtest of the WAB to as-
sess repetition, the informational content subtest of the WAB to assess
single word retrieval in spontaneous speech, the Pyramids and Palm
Trees (PPT) (Howard and Patterson, 1992) test to assess object knowl-
edge, the Boston Naming Test (BNT) (Lansing et al., 1999) to assess
confrontational naming, the Apraxia of Speech Rating Scale (ASRS)
(Strand et al., 2014) to assess the severity of apraxia of speech, and
theMotor SpeechDisorders (MDS) (Yorkson et al., 1993) scale to assess
motor speech production. The presence of agrammatism in speech and
the severity of phonological errors (0= none, 1=mild, 2 =moderate,
3 = severe) was determined by consensus between two speech
language pathologists (JRD and EAS).Aβ (+) Aβ (−) P value
Aβ (+) v Aβ (−)
58 81 NA
2.1 (2.0–2.3) 1.2 (1.2–1.3) b0.001
32 (55%) 38 (47%) 0.34
15 (13–18) 16 (13–18) 0.63
29/53 (55%) 9/67 (13%) b0.001
70 (60–74) 68 (62–73) 0.96
65 (56–70) 66 (59–70) 0.59
3.5 (3.0–5.0) 3.0 (2.0–4.0) 0.04
24 (16–28) 29 (27–30) b0.001
3 (1–4.6) 0.5 (0–1.5) b0.001
b0.001
1 (2%) 14 (17%)
2 (3%) 11 (14%)
47 (81%) 6 (7%)
3 (5%) 13 (16%)
5 (9%) 37 (46%)
Fig. 1. Results of the penalized logistic regression models. Panel A shows the results of the MRI penalized logistic regression model and panel B shows the results of the clinical penalized
logistic regression model. The left panels show the regression coefﬁcients for all variables. The coefﬁcient values on the y-axis are shown as a function of the natural logarithm of the
penalty on the x-axis. The coefﬁcients from the optimal model chosen by cross-validation are indicated by an arrow at a penalty of approximately−3.1 on the log scale. The right
panels show the coefﬁcient estimates for the selected coefﬁcients from the optimal model. In regions with positive coefﬁcients higher volumes (less atrophy and less clinical
impairment) are associated with increased odds of Aβ (+). In regions with negative coefﬁcients lower volumes (more atrophy and more clinical impairment) correspond to increased
odds of Aβ (+). SMA = supplementary motor area; MDS = motor speech disorders scale; ASRS = apraxia of speech rating scale; BNT = Boston naming test; PPT = pyramids and
palm trees test.
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All Aβ PET scans were acquired using a PET/CT scanner (GE
Healthcare, Milwaukee, Wisconsin) operating in 3D mode. Subjects
were injected with Pittsburgh Compound B (PiB) (average, 614 MBq;
range, 414–695 MBq) and after a 40 min uptake period a 20 min PiB
scan was obtained consisting of four 5-min dynamic frames following
a low dose CT transmission scan. Standard corrections were applied.
The automated anatomical labeling (AAL) atlas (Tzourio-Mazoyer
et al., 2002) was used to calculate median PiB uptake for 6 cortical
regions-of-interest (ROIs) which were each divided by median cerebel-
lar uptake to create uptake ratios. A cortical-to-cerebellar (SUVR) ratio
was formed by calculating median uptake ratio values across all 6 re-
gions. Patients were classiﬁed as Aβ (+) using a SUVR ratio cut-point
of 1.5 (Jack et al., 2008). Visual assessment of all Aβ PET scans was
also performed (VJL and JLW) to verify Aβ status. The visual assessment
and SUVR agreed in all but two cases which were visually read aspositive but had low SUVR ratios. These cases were considered Aβ (+)
in subsequent analyses and were excluded from analyses that utilized
the actual SUVR value.
2.4. MRI analysis
All subjects underwent a standardized MRI imaging protocol at 3.0
Tesla that included a 3D magnetization prepared rapid acquisition gra-
dient echo (MPRAGE) sequence. All images underwent pre-processing
that included corrections for gradient non-linearity (Jovicich et al.,
2006) and intensity inhomogeneity using both the N3 bias correction
(Sled et al., 1998) followed by the SPM5-based bias correction.
An atlas-based parcellation technique was employed using SPM5
and the AAL atlas (Tzourio-Mazoyer et al., 2002), in order to generate
regional gray matter volumes. The following 21 mutually exclusive
brain regions-of-interest (ROIs) were analyzed: hippocampus, entorhi-
nal cortex, fusiform cortex, inferior, middle and superior temporal gyri,
Fig. 2. Estimated probability of Aβ (+) from theoptimalMRI and clinical penalized logistic
regression models (y-axis) by the observed Aβ status (x-axis). Estimated probabilities
N0.5 correspond to a model-based prediction of Aβ (+). The distributions for Aβ (−)
and Aβ (+) subjects are summarized with standard box plots indicating the median,
quartiles, and having whiskers extending out to 1.5 times the inter-quartile range.
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gyrus + supramarginal gyrus), superior parietal gyrus, precuneus,
posterior cingulate, orbitofrontal cortex, anteromedial frontal lobe
(superior medial frontal gyrus + medial orbital gyrus), Broca's area
(inferior operculum+ inferior triangularis),middle and superior frontal
gyri, supplementarymotor area (SMA), sensorimotor cortex (precentral
gyrus+paracentral lobule+ postcentral gyrus+ rolandic operculum),
occipital lobe (inferior, superior and middle occipital gyri + lingual
gyrus + cuneus + calcarine gyrus), insula and striatum (left and right
hemispheres were analyzed separately for each region). These regions
were selected to cover all major lobes of the brain and, speciﬁcally,
regions of the brain typically affected by each PPA variant and PAOS.
EachMPRAGEwas normalized to custom template space and the in-
verse transformation was used to warp the custom space AAL atlas to
the patient native anatomical space. Each MPRAGE was segmented
into gray matter, white matter and cerebrospinal ﬂuid in native space
and gray matter volumes were calculated for each region of interest.
In addition, total gray matter volume in mm3 was calculated for eachsubject by summing the gray matter probabilities from the segmenta-
tions and multiplying by the voxel dimensions. All regional volumes
were divided by total gray matter volume to correct for differences in
global atrophy between subjects. This step was performed because we
were interested in assessing the relative involvement of each region
rather than just the global severity of atrophy.2.5. Statistical analysis
All statistical analyses were performed using R version 3.0.2
(http://www.R-project.org) and the glmnet package version 1.9-5.
Comparisons of demographic variables of interest among Aβ (+)
an Aβ (−) groups were performed using Kruskal–Wallis tests for
continuous variables and chi-squared or Fisher's exact tests for cate-
gorical variables.
An “elasticnet” penalized logistic regressionwas used to determine a
parsimonious set of ROIs (MRI model) or clinical tests (clinical model)
that are predictive of Aβ status (Hastie et al., 2001). The candidate
MRI variables were each of 42 ROIs standardized to have mean zero
and SD 1. Prior to modeling, we transformed clinical variables as neces-
sary to obtain approximately normal distributions. The following vari-
ables were negatively skewed with a maximum of 10 and were
transformed via−√(10− x): informational content, repetition, reading
irregular words, reading non-words, writing irregular words, writing
non-words, and MDS. ASRS was right-skewed and was square-root
transformed. To aid interpretation, we wanted higher values to corre-
spond to “better” performance across all variables and therefore we re-
versed the sign for agrammatical and phonological errors. All variables
were then standardized to have mean zero and SD 1. The clinical
model was run using all subjects that had scores for all 14 speech and
language variables (n = 132). Seven subjects who could complete the
MRI were unable to complete the entire clinical battery used in the
models due to severity, such as beingmute. The alpha tuning parameter
was set to 0.8 so that the penalty was primarily constraining the sum of
the absolute value of the coefﬁcients which favors amore parsimonious
model, but also partly constraining the sum of the squared coefﬁcients
which helps stabilize coefﬁcientswhen there aremany are highly corre-
lated variables (Hastie et al., 2001). To obtain aﬁnalmodel,we used ten-
fold cross validation and selected the penalty so as to minimize cross-
validation error, deﬁned as the change in model deviance. We call this
the “optimal” model and use it to calculate predicted probabilities.
When the predicted probability was 0.5 or greater, we classify subjects
as Aβ (+). The area under the ROC curve (AUROC) for these predictions,
also known as the C statistic in logistic regression, was used to evaluate
howwell themodels separated Aβ (+) fromAβ (−) subjects.Multivar-
iablemodel ﬁtting incorporating penalized coefﬁcients or “shrinkage” is
preferable to model selection strategies such as stepwise regression be-
cause the latter tends to over-ﬁt and bias coefﬁcients away from the null
(Harrell, 2001).
In order to provide an imaging tool that could be useful clinically, we
ﬁt a binary classiﬁcation tree using the rpart package in R to identify a
parsimonious model that could serve as a rough surrogate, or ﬁrst
order approximation, to the full penalized logistic regression model
described above (Therneau and Atkinson, 1997). In ﬁtting the tree
model we considered as predictors only those regions selected by the
penalized logistic model. For each of these candidate regions atrophy
was classiﬁed as mild, moderate, or severe. This was done by ﬁrst
converting the regional volume divided by gray matter volume to a z
score and then trichotomizing these z scores based on cut-offs corre-
sponding to 33.3rd and 66.7th percentiles of a standardnormal distribu-
tion (z scores of−0.43 and +0.43). The classiﬁcation tree algorithm is
recursive such that for any set of subjects it identiﬁes which region can
be used to best divide subjects into relatively homogeneous groups in
terms of their Aβ status. Cross-validation was used to “prune” the tree
model to prevent overﬁtting.
Fig. 3.Dot plots showing regional graymatter volume expressed as a percentage of total graymatter volume stratiﬁed byAβ status for each of 14 regions included in the optimal penalized
logistic regression model. The distributions for all Aβ (−) and Aβ (+) subjects are summarized with standard box plots in the middle of each panel indicating the median, quartiles, and
having whiskers extending out to 1.5 times the inter-quartile range. Clinical diagnoses are indicated with different symbols.
Fig. 4. Binary classiﬁcation tree to predict Aβ status based on atrophy levels (mild,
moderate or severe) in four regions. If the left superior temporal gyrus shows no
atrophy or only mild atrophy then the case would be classiﬁed as Aβ (−). However, if
the left superior temporal gyrus shows moderate or severe atrophy, one should consider
the left hippocampus, right SMA and right superior parietal lobe. If the left hippocampus
and right superior parietal lobe are both severely atrophic then the case would be
classiﬁed as Aβ (+). If the left hippocampus is not severely atrophic then the case can
only be classiﬁed as Aβ (+) if the right SMA is relatively spared. SMA= supplementary
motor area.
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The demographic features of the cohort are shown in Table 1. Of the
139 subjects in the study, 58 (42%) were Aβ (+). There was no differ-
ence in age at onset, age at examination, gender or education between
the Aβ (+) and Aβ (−) subjects, although the Aβ (+) subjects had
slightly longer disease duration. The Aβ (+) subjects performed
worse on the Mini-Mental State Examination and clinical dementia rat-
ing scale, and had a higher proportion of apolipoprotein e4 carriers than
the Aβ (−) subjects. Three Aβ (−) subjects had mutations in
progranulin and one Aβ (−) subject had a C9ORF72 repeat expansion.
The majority (81%) of the Aβ (+) subjects were diagnosed with
lvPPA, whereas the different clinical diagnoses were more evenly split
across the Aβ (−) group. The proportion of Aβ (+) subjects differed
across the different clinical syndromes (p b 0.0001),with a high propor-
tion of Aβ (+) subjects observed in the lvPPA group (89%), and a lower
proportion observed in the UCPPA (19%), svPPA (15%), PAOS (12%) and
agPPA (7%) groups.
The optimal penalized binary logistic regression models for MRI and
clinical are shown in Fig. 1. Classiﬁcation accuracy of both models is
shown in Fig. 2. The MRI model accurately classiﬁed the Aβ status of
113/139 (81%) subjects using 14 variables. Classiﬁcation was achieved
with an AUROC of 0.87, sensitivity of 69% (40/58 Aβ (+) correctly clas-
siﬁed) and speciﬁcity of 90% (73/81 Aβ (−) correctly classiﬁed). The
model included a combination of regions inwhich smaller volumes pre-
dicted Aβ (+) status (i.e. negative coefﬁcients) and regions in which
larger volumes predicted Aβ (+) status (i.e. positive coefﬁcients). The
regions inwhich small volumes predicted Aβ (+) included left superior
temporal gyrus, left inferior and superior parietal lobes, right inferior
and superior parietal lobe, right inferior, middle and superior temporal
gyri and left orbitofrontal cortex. The regions in which larger volumes
Fig. 5.Dot plots and bar charts showing the 12 speech and language tests included in the optimal penalized logistic regressionmodel stratiﬁedbyAβ status. The distributions for all Aβ (−)
andAβ (+) subjects are summarizedwith standardboxplots in themiddle of eachpanel indicating themedian, quartiles, andhavingwhiskers extending out to 1.5 times the inter-quartile
range. Clinical diagnoses are indicated with different symbols. MDS =motor speech disorders scale; BNT = Boston naming test; PPT = pyramids and palm trees test.
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right supplementary motor area and right sensorimotor cortex. Dot-
plots showing each of these 14 regions stratiﬁed by Aβ status are
shown in Fig. 3. In addition, a classiﬁcation tree based on this model is
shown in Fig. 4. As with the full model, this classiﬁcation tree results
in an accuracy of 81% in predicting Aβ status.
The clinical model accurately classiﬁed the Aβ status of 109/132
(83%) subjects using 12 clinical tests. Classiﬁcation was achieved with
an AUROC of 0.93, sensitivity of 78% (43/55 Aβ (+) correctly classiﬁed)
and speciﬁcity of 86% (66/77 Aβ (−) correctly classiﬁed). More severe
phonological errors, repetition deﬁcits, abnormalities in writing irregu-
lar words, poor performance on the information content subtest of the
WAB, poor performance on the PPT, poor performance on the BNT, pre-
served motor speech, preserved reading of irregular words and writing
non-words, and absence of agrammatism in speech predicted Aβ (+).
The Token Test also contributed to the model. Dot-plots showing each
of these 12 clinical tests stratiﬁed by Aβ status are shown in Fig. 5.
A preliminary analysis assessing performance of the models within
each clinical diagnostic group is shown in Fig. 6 and Table 2. Within
the lvPPA group, the MRI model correctly classiﬁed 5/6 of the Aβ (−)
subjects, but falsely classiﬁed10 subjects as Aβ (−). In contrast, the clin-
ical model classiﬁed nearly all lvPPA subjects as Aβ (+). Neither model
correctly classiﬁed the Aβ (+) subjects within the agPPA and PAOS
groups. The clinical model performed somewhat better in the svPPAgroup correctly classifying both Aβ (+) subjects. The MRI model was
able to correctly classify 14/16 (87.5%) UCPPA subjects compared to
only 10/15 (66.7%) in the clinical model.
Performance of bothmodels can be compared to the performance of
clinical diagnosis. If one assumes based on previous studies that lvPPA
subjects will be Aβ (+) and the svPPA, agPPA and PAOS subjects will
be Aβ (−), then clinical diagnosis accurately classiﬁes 109/123 (89%)
subjects. The 16 UCPPA subjects cannot be included in this analysis
since we did not know the Aβ status of these subjects a priori and
hence could not predict whether they would be Aβ (+) or Aβ (−). In
comparison, excluding the UCPPA subjects, the MRI model accurately
classiﬁed 99/123 (80%) of subjects and the clinical model accurately
classiﬁed 99/117 (85%) of subjects.
4. Discussion
This study assesses the value of MRI and clinical data in predicting
Aβ status in a large cohort of 139 PPA and PAOS subjects. We showed
that the optimal MRI and clinical models performed comparably in
overall prediction of the presence of Aβ deposition, correctly classifying
Aβ status in 81% and 83% of subjects respectively, although the predic-
tion accuracy of clinical diagnosis alone outperformed both models.
The models, particularly the MRI model, may, however, still be of
value in subjects that cannot be diagnosed clinically.
Fig. 6. Scatter plots showing the estimated probability of Aβ (+) from the optimal
penalized logistic regression model (y-axis) versus the observed Aβ value (x-axis) by
clinical diagnosis. Panel A shows the results for the MRI model and panel B shows the
results for the clinical model. A vertical line at 1.5 deﬁnes Aβ status while a horizontal
line at 0.50 indicates the cut-point for predicting Aβ (+). Subjects in the top right or
lower left quadrants are correctly classiﬁed by the model.
Table 2
Classiﬁcation accuracy within each diagnostic group.
Dx Observed Aβ MRI model
classiﬁcation
Clinical model
classiﬁcation*
Aβ (+) Aβ (−) Aβ (+) Aβ (−)
agPPA Aβ (+) 0 1 0 1
Aβ (−) 1 13 1 13
svPPA Aβ (+) 1 1 2 0
Aβ (−) 3 8 2 8
lvPPA Aβ (+) 37 10 40 4
Aβ (−) 1 5 4 1
UCPPA Aβ (+) 2 1 1 2
Aβ (−) 1 12 3 9
PAOS Aβ (+) 0 5 0 5
Aβ (−) 2 35 1 35
* The clinical model excluded seven subjects that could not complete all testing.
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classiﬁcation of Aβ status. Involvement of both left and right
temporoparietal regions and left orbitofrontal cortex, with a sparing of
Broca's area, supplementarymotor cortex, left hippocampus and senso-
rimotor cortex, was predictive of the presence of Aβ deposition. These
ﬁndings concord with previous smaller pathological studies showing
that temporoparietal atrophy is associated with the presence of AD pa-
thology in subjects presenting with atypical clinical syndromes
(Lehmann et al., 2010; Lee et al., 2011; Whitwell et al., 2010, 2011).
Interestingly, in the current study, both left and right temporoparietal
regions were useful for classiﬁcation, despite the fact that PPA is
predominantly associated with involvement of the left hemisphere.
Subjects with Aβ deposition are, therefore, more likely to show involve-
ment of both temporoparietal cortices compared to subjectswithout Aβ
deposition. Temporoparietal atrophy has, indeed, been observed inlvPPA subjects with AD pathology (Gorno-Tempini et al., 2004;
Madhavan et al., 2013), with atrophy typically starting in the left hemi-
sphere but then spreading to involve the right hemisphere over time
(Rohrer et al., 2013). Of note, only lateral temporoparietal regions
were predictive of Aβ status, with precuneus and posterior cingulate
not adding any additional discriminative power and hence not
appearing in the 14 regions that provided optimum classiﬁcation, de-
spite the fact that they can also be atrophic in lvPPA. It is likely that
these regions are less useful because they are typically affected to a less-
er degree than lateral temporoparietal regions in lvPPA (Ridgway et al.,
2012; Botha et al., 2015). The fact that large volumes of Broca's area,
supplementary motor area, sensorimotor cortex and left hippocampus
were predictive in the model, may either suggest that when these re-
gions are involved, subjects are less likely to have Aβ deposition, or
may suggest that these regions are spared in subjects with Aβ deposi-
tion; or perhaps a combination of both. Broca's area is typically atrophic
in agPPA (Gorno-Tempini et al., 2004;Whitwell et al., 2013), the supple-
mentary motor area is typically atrophic in PAOS (Josephs et al., 2012,
2013; Whitwell et al., 2013), and the left hippocampus is usually atro-
phic in svPPA (Chan et al., 2001); all of which are usually associated
with non-AD pathology. The sensorimotor cortex can become involved
in PAOS (Josephs et al., 2013), but is also a region that is typically spared
in subjects with AD pathology (Whitwell et al., 2007). Our model is
therefore somewhat dependent on the composition of our Aβ negative
cohort. Fig. 4 shows a classiﬁcation tree that provides an approximation
of the larger imagingmodel to provide a tool that could be clinically use-
ful for predicting Aβ status. Assessing the degree of atrophy of the left
superior temporal gyrus, left hippocampus, right supplementary
motor area and right superior parietal lobe can help a clinician to predict
Aβ status with the same degree of accuracy as the full model.
The clinical model identiﬁed 12 speech and language variables
which provided optimum classiﬁcation of Aβ status. The variables
which were most strongly associated with Aβ deposition were phono-
logical errors, the presence of deﬁcits in repeating complex sentences
and errors in writing irregular words. The absence of agrammatism,
the absence of errors in reading irregular words and the absence of
motor speech abnormalities were also highly predictive of Aβ deposi-
tion. The presence of phonological errors and repetition deﬁcits are
features that are typically associated with lvPPA, and absent in agPPA,
svPPA and PAOS, as we observed in our cohort (Supplemental
Table 1). Deﬁcits in spelling irregular words have been previously
observed in PPA (Sepelyak et al., 2011), and the lvPPA subjects in our co-
hort performed poorly on this task (Supplemental Table 1). Conversely,
the presence of agrammatism and motor speech abnormalities are
features of agPPA and PAOS that are typically absent in lvPPA, as we
observed in our cohort (Supplemental Table 1). Deﬁcits in reading irreg-
ular words have been associated with svPPA (Patterson et al., 2001). A
couple of other studies have also investigated clinical features that
help predict Aβ deposition. Despite the fact that the cohorts in these
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they also found that phonological errors were highly predictive of Aβ
deposition (Chare et al., 2014; Leyton et al., 2014).
Performance of theMRI and clinical models differed when each spe-
ciﬁc clinical diagnosis was examined. In subjects with lvPPA, the clinical
model tended to predict that all subjects will be Aβ (+), while the MRI
model could identify 5/6 of the Aβ (−) subjects, but also made a num-
ber of false Aβ (−) calls. Indeed, we have previously shown that Aβ (−)
lvPPA has a different atrophic signature to Aβ (+) lvPPA, with more
highly asymmetric atrophy and greater involvement of the anterior
temporal lobes (Whitwell et al., 2015). However, the clinicalmodel per-
formed better than the MRI model in svPPA, correctly classifying both
Aβ (+) subjects with only two false positives. The Aβ (+) svPPA sub-
jects were likely correctly classiﬁed because both showed mild phono-
logical errors and repetition deﬁcits (Supplemental Table 1). The
presence of these clinical features could therefore be an important
clue to the presence of Aβ deposition in svPPA. The number of Aβ (+)
svPPA subjects was, however, small and so these ﬁndings will need to
be validated in a larger cohort. Neither the MRI nor clinical model was
able to predict the few subjects in the agPPA or PAOS groups who
were Aβ (+). This could suggest either that the Aβ (+) subjects in
these groups do not have a different MRI or clinical signature than the
typical Aβ (−) subjects, or that our model was unable to identify subtle
differences in these few subjects, possibly due to the small number of
subjects. We favor the ﬁrst explanation given that we could not identify
any discernible differences in the patterns of atrophy or clinical perfor-
mance on visual inspection. It is possible that Aβ deposition in these
agPPA and PAOS subjects may represent a secondary pathology, possi-
bly a diffuse Aβ plaque pathology (Kantarci et al., 2012), co-occurring
with FTLD pathology (Kertesz et al., 2005; Mesulam et al., 2014),
explainingwhy it does not signiﬁcantly alter the pattern of neurodegen-
eration as previously hypothesized (Josephs et al., 2014). Alternatively,
the topographic distribution of AD pathology could be atypical in these
cases. Autopsy conﬁrmationwill be needed to determine the underlying
pathology in these subjects.
Interestingly, the MRI model performed well in the UCPPA subjects.
Of the 16 UCPPA subjects, three were Aβ (+) and the model correctly
predicted two of these three. The third casewas, however, onlymargin-
ally Aβ (+) with a SUVR of 1.51, and hence the Aβ status was border-
line. The model also correctly classiﬁed 12 (92%) of the 13 Aβ (−)
UCPPA subjects, with the ﬁnal case given a borderline estimated Aβ
probability of 0.500 by the model. Therefore, despite the fact that the
clinical diagnosis is uncertain, the presence of Aβ is associatedwith spe-
ciﬁc MRI imaging signatures in these cases. Patterns of atrophy could
therefore be useful to help determine which of these cases will likely
have Aβ deposition. This information could then be used to select
which individuals should undergo more costly Aβ PET scanning. This
was particularly important since inmany of the UCPPA cases the clinical
dilemma was between lvPPA and the Aβ (−) diagnoses. The clinical
model did not perform as well, correctly classifying only one of the Aβ
(+) subjects and 75% of the Aβ (−) subjects, suggesting that clinical
data will not be as useful in the UCPPA subjects. Since speech and
language tests are used to help guide clinical diagnosis this is perhaps
unsurprising.
Overall performance of the MRI and clinical models was good with
similar predictive accuracy, with the MRI model correctly classifying
81% of subjects and the clinical model correctly classifying 83% of sub-
jects. However, both models were outperformed by clinical diagnosis
which could correctly classify 89% of subjects. One thing to consider,
however,when using clinical diagnosis alone is that itwill be impossible
to identify discordant cases, i.e. Aβ (−) lvPPA subjects and Aβ (+)
agPPA, svPPA and PAOS subjects. Performance of clinical diagnosis in
our cohort was excellent because we had relatively few discordant
cases, but other cohorts have reported large proportions of discordant
cases. Studies have reported that up to 46% of lvPPA subjects do not
have Aβ deposition (Harris et al., 2013) and, for example, up to 30% ofagPPA subjects do have Aβ deposition (Chare et al., 2014). In fact, in
one recent large clinicopathological study, a clinical diagnosis of lvPPA
had sensitivity of only 50% and a speciﬁcity of 71% in identifying AD pa-
thology within subjects with PPA (Mesulam et al., 2014). Furthermore,
utilizing clinical diagnosis would make it impossible to be able to pre-
dict Aβ status in the UCPPA subjects that do not fulﬁll clinical criteria
for one of the PPA variants, which can be a large proportion of subjects
(Sajjadi et al., 2012; Wicklund et al., 2014).
A major strength of our study is the large cohort of subjects with Aβ
PET imaging and MRI. We included all prospectively recruited subjects
that met clinical inclusion criteria in our study and did not exclude
left-handed subjects or impose quantitative cut-offs, in order that our
results would generalize as much as possible to other cohorts of PPA
and PAOS subjects. A number of our subjects showed poor scores on
the Mini-Mental State Examination (Supplemental Table 1) suggesting
cognitive impairment. However, in many instances performance was
affected by naming difﬁculties or the presence of apraxia of speech.
Nevertheless, our cohort is consistent with cohorts from other centers
that similarly show low Mini-Mental State Examination scores in PPA,
particularly in lvPPA (Sajjadi et al., 2012; Lehmann et al., 2013; Leyton
et al., 2013). It will, however, be important to validate our ﬁndings in
other cohorts to determine whether our ﬁndings generalize to cohorts
with different diagnostic compositions and different proportions of sub-
jects with Aβ deposition.We also adjusted all regional volumes by total
graymatter volume to ensure our resultswere not driven by differences
in severity. A limitation of the study is the small number of discordant
caseswithin each clinical diagnosis. The analysis of how themodels per-
form in these cases should therefore be considered preliminary andwill
need to be validated in larger cohorts. Another possible limitation was
that we did not assess white matter, instead choosing to focus on gray
matter structures. Future studies will be needed to determine whether
the inclusion of white matter metrics and also, potentially, CSF bio-
markers, may help further improve classiﬁcation.
5. Conclusions
These ﬁndings demonstrate that neuroimaging and speech and
language data both have the potential to be useful to predict the pres-
ence of Aβ deposition, and could prove to be useful if Aβ imaging is un-
available. While clinical diagnosis provided superior prediction at the
group level, these models, particularly the neuroimaging model, may
be valuable to predict Aβ status in UCPPA.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2016.01.014.
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